Participated · Series B · Aug 2026

QuantHealth offers an AI-driven clinical trial simulation platform that enables life sciences companies to evaluate, optimize, and de-risk clinical and commercial decisions before enrolling patients or committing capital. The company serves pharmaceutical and biotechnology organizations and is led by CEO Orr Inbar. QuantHealth is based in Tel Aviv, Israel. Following its Series B, the company plans to scale enterprise-wide impact, accelerate adoption of simulation-first clinical development, advance R&D capabilities, grow its workforce, and expand its product portfolio. The article does not disclose revenues, user counts, or prior funding rounds.

Participated · Equity · Apr 2026

Osteoboost Health Inc. develops a wearable Class II prescription device worn around the hips that delivers low-magnitude vibration therapy to the lumbar spine and hips as a non-drug treatment for low bone density and osteopenia, particularly in postmenopausal women. The treatment approach is based on research originally funded by NASA and, in a double-blind trial at the University of Nebraska Medical Center, users who adhered to at least three 30-minute sessions per week for 12 months saw bone density loss reduced by 85% in the spine and 55% in the hips, per the company. The device received a Breakthrough Device designation in 2024 and was later cleared via the FDA De Novo pathway; the company began shipping in May. Since launch it has been prescribed by more than 2,500 physicians, including clinicians at over 30 academic medical centers. The company was also named to TIME’s 2025 list of Best Inventions. Osteoboost plans to use the new financing to scale manufacturing, expand clinical research, and broaden commercialization.

Led · Seed · Nov 2025

No Barrier is a San Francisco–based health-tech company building an AI-driven, real-time language interpretation platform for healthcare providers. The software embeds into existing electronic health record (EHR) systems with HIPAA-grade security, giving clinicians instant access to interpretation services for limited-English-proficiency (LEP) patients. Its solution is live in more than 100 healthcare sites across 12 U.S. states, covering hospitals and specialties such as mental health, reproductive care, and pediatrics. By eliminating wait times for translators and preserving patient privacy, the product aims to improve clinical outcomes and operational efficiency. The company generates revenue by selling its platform to health systems and individual providers, though specific revenue figures were not disclosed. With fresh capital, management plans to accelerate product development and broaden commercial deployment. Future initiatives include deeper EHR workflow integrations and expansion to additional specialties and geographies.

Participated · Series A · Sep 2025

Neura Health operates a virtual neurology clinic aimed at improving access and quality of care for patients suffering from chronic neurological conditions such as migraine, sleep disorders, seizures, TBI, stroke, tremors, long COVID, and memory disorders. The platform combines tele-neurology visits with integrated symptom tracking, personalized educational content, and dedicated care coaching. Since launch, the company has treated more than 43,000 patients across the United States and partners with health systems like Sentara Health to extend neurology capacity. It is in-network with over 40 health plans, including Aetna, Blue Shield of California, Cigna, Anthem Blue Cross, TriWest, and Medicare, which broadens patient affordability and reach. Co-founded by Elizabeth Burstein and Sameer Madan, Neura Health plans to use new capital to scale operations and advance product development. The company has now raised a cumulative $22 million in venture funding, reflecting growing investor confidence in its tele-neurology approach. No revenue figures were disclosed in the article, but the patient volume and payer relationships indicate early commercial traction.

Led · Seed · Feb 2025

Cerula Care delivers a team-based, cancer-specific behavioral health and care navigation platform that integrates directly with oncology practices. The company operates a virtual-first model offering counseling, health coaching, and psycho-oncology to improve quality of life for people undergoing cancer treatment. Cerula launched in 2024 with three large oncology practices and has reported statistically significant improvements in somatic symptoms, quality of life, anxiety, and depression within three months of care. Those clinical gains have translated into greater adherence to cancer care plans and a decrease in unwanted hospitalizations. The company raised an oversubscribed $3.7 million Seed round to scale operations. Cerula plans to use the new funding to expand services to more practices and invest in patient-facing technology.